83 results about "Mouse Melanoma" patented technology

The invention provides a preparation method and an application of a cold-fever tablet. The cold-fever tablet is prepared by using 168 g of isatis roots, 126 g of schizonepeta ears, 126 g of bistort roots, 126 g of pueraria mirifica and 126 g of radix bupleuri as raw material drugs via supercritical extraction and microwave-assisted extraction, so that puerarin content in the tablet is increased greatly. The invention also provides the application of the cold-fever tablet in preparing the drug of inhibiting cell proliferation of mouse melanoma lung metastatic lines B16-F10.

The invention discloses application of A-nor-5 alpha-androstane compounds in preparation of malignant tumor resistant medicaments. The compounds have the following general formula I, and comprise Ia, Ib, Ic, Id, Ie and If. The growth inhibition rate of the A-nor-5 alpha-androstane compounds for in-vitro human liver cancer cell Hep 3B, human breast cancer MDA-MB-231, human lung adenocarcinoma A549 and mouse melanoma B16 is higher than 85% on average, and even up to 99.98% to the maximum. The in-vivo test proves that the inhibition rate of the A-nor-5 alpha-androstane compounds for mouse tumors, such as intestinal cancer C26, liver cancer H22, Lewis lung cancer, breast cancer, B16 melanoma and the like, is higher than 50% on average, and even up to 63.19% to the maximum. The result proves that the compounds disclosed by the invention have an obvious malignant tumor resistant action. The A-nor-5 alpha-androstane compounds disclosed by the invention have an obvious and broad-spectrum action on inhibiting growth of malignant tumor cells, and are novel targeted malignant tumor resistant medicaments with low drug toxicity and favorable treatment effect; and the A-nor-5 alpha-androstane compounds just specifically act on tumor cells, but not influence normal cells, thereby having a high clinical application value.

Disclosed are an anti-tumor agent, beverages and foods using the same and a process for manufacturing the anti-tumor agent. The anti-tumor agent according to the present invention exhibits specific effects on human tumor cells A4573 and mouse melanoma B16 cells in vitro. The anti-tumor agent exhibits various immune activities in addition to immune activity against tumors. Beverages and foods containing said anti-tumor agent can be manufactured as health food or the like.

The invention discloses a preparation method of a quercetin amide derivative and application of the quercetin amide derivative in preparing an antitumor drug. The preparation method of the quercetin amide derivative comprises the following steps of: carrying out benzyl selective protection, a Williamson ether forming reaction, a DCC (Dicyclohexylcarbodiimide) condensation reaction, catalytic hydrogenation and the line by using cheap rutin as the material. The preparation method of the quercetin amide derivative can be used for realizing the orientation and efficient modification of the quercetin, and is gentle in reaction conditions, simple to operate, simple in post-treatment and convenient for industrial production. The obtained quercetin amide derivative obviously has a stronger inbibitional effect to proliferation of a human esophageal squamous carcinoma cell EC (Ethyl Cellulose)109, a human esophageal squamous carcinoma cell EC9706, a human gastric carcinoma cell SGC (Soluble Guanylyl Cyclase) 7901 and a mouse melanoma cell B16-f10 relative to the quercetin, and therefore, the quercetin amide derivative is an anti-tumor candidate compound with great potential.

A composition based on labdane-diterpenoids that provides better photo protection against both UV A and UV B radiations in the HaCaT human keratinocyte cell lines is disclosed. The composition comprises 8,13-epoxy-1α,6β,7β,9α-tetrahydroxylabd-14-en-11-one alone and in combination with 6β-acetoxy-8,13-epoxy-1α,7β,9α-trihydroxylabd-14-en-11-one and/or 7β-acetoxy-8,13-epoxy-1α,6β,9α-trihydroxylabd-14-en-11-one. The composition protects the cells of the skin from harmful UV A and UV B rays through synergistic mechanisms with utility as a safe long-term cosmetic solution for preventing UV-induced skin damage and to induce sunless tanning. Additionally, the composition enhances melanogenesis in B16F1 mouse melanoma cells acting as tanning inducers/accelerators both in the presence or absence of sunlight. Elevation of melanogenesis confers additional protection against UV-induced skin damage.

The invention discloses application of a compound or a pharmaceutically acceptable salt or ester or a solvate compound in the preparation of a PD-1/PD-L1 small-molecule inhibitor medicament. Potentially active candidate molecules in the compound library are virtually screened out by computer simulation. By using the homogeneous time-resolved fluorescence technique, high-throughput screening of candidate molecule antagonistic PD-1/PD-L1 binding is performed, and a compound with good activity is selected to perform mouse melanoma B16-F10 tumor-transplanting experiments. Then, it is confirmed that the compounds screened by the invention have the antitumor activity.

The invention mainly relates to application of ginsenoside Ro in the preparation of antitumor drugs. Experiments for studying on changes in the size of tumors of a mouse injected with ginsenoside Ro show that early inhibition rate for the growth of tumors in the mouse injected with the ginsenoside Ro is substantially unchanged and the tumors enlarge synchronously with tumors in model group animals; after entering logarithmic growth stage, the ginsenoside Ro has enhanced inhibitory action on the enlargement of the tumors, and the inhibition rate is significantly higher than the tumor growth inhibitory action in slow growth stage; it is proved that the ginsenoside Ro has good inhibitory action on mouse melanoma. According to tests for researching change of tumor weight of the mouse injected with the ginsenoside Ro, the ginsenoside Ro has good inhibitory action on the melanoma and can be prepared into new antitumor drugs.

The invention discloses a peganum harmala lipid transfer protein (PHP) and relates to the preparation and use of new protein with antifungal, anticancer and antivirus activities. The method uses seeds of a peganum harmala plant as raw materials and comprises the following steps: preparing a coarse product, performing cationic exchange chromatographic separation and purifying by using a molecular sieve; and gradually separating and collecting a purified component having antibacterial activity, dialyzing, desalting, freeze-drying and thus, obtaining purified PHP. In the invention, a filter paper disc agar diffusion method is adopted, and researches prove the protein has growth inhibiting effect on five plant pathogenic fungi, namely alternaria alternate, penicillium degitatum, rhizopus stuolonifer, magnaporthe grisea and penicillium italicum. An 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method proves that the protein has inhibiting effect on proliferation of human esophageal carcinoma cell Eca109, human cervical cancer cells HeLa, human stomach cancer cells MGC-7, mouse melanoma cells B16 and the like. The protein can inhibit the activity of human immunodeficiency virus 1 (HIV-1) reverse transcriptase. The protein can be used for developing medicines for resisting agricultural pathogenic fungi, tumors and viruses.

Embodiments of the invention provide mouse tumor models involving either the B16 mouse melanoma or MXT mouse mammary tumor, untreated or treated with chemotherapy and/or anti-cachectic agents, for the study of tumor-generated or cancer therapy-generated cachexia-inducing signals and mechanisms. Other embodiments of the invention also provide additional models, including pre-treatment of mouse skin with anti-cachectic proteins prior to tumor implantation, for the study of anti-cachectic signals and mechanisms generated by the skin. To reduce or reverse tumor- and chemotherapy-induced cachexia, embodiments of the invention use the human proteins placental alkaline phosphatase, transferrin, α₁-antitrypsin preparations or combinations thereof as well as chemically synthesized CCDTHT or N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]-ethanaminium iodide or CCDTHT-like compounds.

The invention relates to the field of medicine synthesis and discloses a preparation method and application of a 3H-1,2-dithiole-3-thioketone compound. According to the preparation method of the 3H-1,2-dithiole-3-thioketone compound shown in a formula I described in the specification, the yield of the 3H-1,2-dithiole-3-thioketone compound is improved, the problem of unsafe operation in the production of hexamethyl disiloxane is solved, the environmental pollution is reduced, the preparation method is simple to operate, a vulcanization accelerator is low in price and easy to obtain, the production cost is reduced, and the preparation method is suitable for batch preparation of the 3H-1,2-dithiole-3-thioketone compound shown in the formula I. Furthermore, the 3H-1,2-dithiole-3-thioketone compound shown in the formula I plays a suppression role in multiplication of a human liver cancer HePg2 cell strain, a human lung cancer A549 tumor cell strain, a mouse melanoma B16 tumor cell strain and a human liver cancer SMMC-7721 tumor cell strain, and can be used for preparing antitumor medicines.

The invention relates to supernatant cultivated by DCIK cells and an application thereof. The supernatant and a preparation of freeze-dried powder prepared by frozen, dried and concentrated supernatant have good anti-tumor activity in tumor therapy. The supernatant cultivated by DCIK cells contains a series of mixtures of cytokines with biological activity which directly act on cell lines cultivated in vitro, thereby causing the forms of the cell lines such as mice melanoma B16 and THP-1 etc. to be affected and producing growth inhibition. The anti-tumor in vivo experiment shows that the supernatant cultivated by DCIK cells and the preparation of freeze-dried powder thereof can obviously inhibit the growth of the mouse melanoma B16 inoculated subcutaneously without obvious side effect. The invention fully proves the prospects of application and research of supernatant cultivated by DCIK cells, and paves the new way for the research of anti-tumor drugs.

The invention discloses application of a compound (QB) shown in a formula I in preparation of medicines for prevention and/or treatment. The MTT experiment displays that the proliferation inhibition effects of the compound QB on the four tumor cells, such as human esophageal squamous carcinoma cell EC109, the human esophageal squamous carcinoma cell EC9706, the human gastric carcinoma cell SGC7901 and mouse melanoma cell B16-F10, are obviously superior to those of quercetin. The inhibition effect of (IC50=5.201mu g/mL) on the EC109 cells is equivalent to that of fluorouracil 5-FU(IC50=5.426mu g/mL), the toxic or side effect is relatively small, and the compound is a potential antitumor candidate compound.

The present invention relates to an oncolytic adenovirus simultaneously expressing interleukin-12 and shVEGF, and an antitumor immunity enhancing composition and an anticancer effect promoting composition each containing the same. The present inventors verified that the simultaneous occurrence of VEGF inhibition and IL-12 expression induced the recovery of an immune function and the promotion of an anticancer effect in an immunological mouse melanoma or kidney cancer model. Especially, the applicability of a gene carrier simultaneously expressing IL-2 and shVEGF in the cancer gene therapy was first established by disclosing that the increased anticancer effect is involved in an increase in anticancer immunity, an increase in TH 1 cytokine, and the prevention of tumor induced thymic atrophy.

A cancer vaccine technology is provided which knocks out expression of cell surface immune checkpoint proteins, to facilitate their processing by immune cells, and optionally by knocking-in the expression of cytokines to boost immune response. Non-replicating tumor cells lacking cell surface CD47 are highly effective immunizing agents against subcutaneous mouse melanoma. Whole-cell vaccines inhibited tumor growth, and immunophenotyping showed a dramatic increase in activated effector cell subsets and M1-type macrophages aided by a significant reduction in the tumor-associated macrophage and myeloid derived suppressor cell compartments. A remarkable downregulation of cell surface CD47 was observed in the tumors that did escape after vaccination with genetically modified cells, suggesting the intricate involvement of CD47 in a prophylactic situation. An effective vaccination strategy to increase tumor-specific immune response in solid tumors is provided to improve the outcome of cancer immunotherapy.

The invention provides a preparation method for a liver-restoring tablet. The liver-restoring tablet is prepared from the bulk drugs consisting of 800 g of isatis root, 166 g of oriental wormwood, 266 g of curcuma tuber, 266 g of Chinese magnoliavine, 266 g of licorice, 133 g of Chinese angelica, 400 g of milk vetch and 200 g of acanthopanax root through supercritical extraction. With the preparation method, the content of the bulk drugs in the liver-restoring tablet is greatly increased, and the dose of the tablet is reduced. The invention further provides application of the liver-restoring tablet in preparation of drugs used for inhibiting cell proliferation of the mouse melanoma lung metastasis strain B16-F10.

The invention provides a preparation method for Torvosaurus liquid. The Torvosaurus liquid is prepared by taking 25g of male silk moth, 25g of acanthopanax, 17.5g of wine-processed semen cuscutae, 20g of herba epimedii, 10g of salt-processed prepared rehmannia root and 10g of salt-processed fructus psoraleae as raw material medicines; the Torvosaurus liquid is prepared by microwave extraction, so that the Torvosaurus content is greatly increased, and the dose is reduced. The invention also provides the application of the Torvosaurus liquid in preparing drugs for restraining murine melanoma 16B cell proliferation and drugs for treating or preventing dengue virus infection.

The invention discloses a naphthaquinone compound derived from marine microbes, and a preparation method and application thereof. The systematic name of the compound is 1,2,3,4-tetrahydro-1,2,5-trihydroxy-6,7-dimethoxy-3-methyl-9,10-anthracenone, and the structure is disclosed as Formula (I). The naphthaquinone compound can be continuously obtained by fermentation. The compound has the advantages of high antineoplastic activity, environment friendliness and low use cost, and can be used for preparing antineoplastic drugs. The active naphthaquinone compound derived from microbes is small in amount and simple in structure, and can be used as a precursor of antineoplastic drugs; the structural modification and reconstruction on the basis of the prior art enhance the antineoplastic targeting property and efficiency; and when being used for developing drugs for treating human stomach cancer, human lung cancer, mouse melanoma, human mammary cancer, human pancreatic cancer, human cervical carcinoma, human osteogenic sarcoma, human liver cancer, human colon cancer and human laryngocarcinoma, the naphthaquinone compound has wide application prospects.

The invention provides a preparation method of a breast lump dissipating tablet. The breast lump dissipating tablet is prepared from bulk drugs, including 825g of tangerine leaves, 825g of roots of red-rooted salvia, 550g of spina gleditsiae, 550g of seeds of cowherb, 550g of szechwan chinaberry fruit, and 550g of earthworms, through supercritical extraction, so that the content is improved greatly, and the dose is reduced. The invention also provides an application of the breast lump dissipating tablet in the preparation of medicines for inhibiting cell proliferation of mouse melanoma lung metastatic lines B16-F10.

The invention relates to a use of a TNFSF15 protein in the preparation of a melanoma treatment medicine. It is found that the TNFSF15 can inhibit the growth of endothelial cells and induce the apoptosis of the endothelial cells, and also can inhibit the growth and migration of mouse melanoma cells B16 and induce the apoptosis of the mouse melanoma cells B16. When the TNFSF15 and a chemotherapeuticmedicine are simultaneously used to treat melanoma, the TNFSF15 can inhibit the generation of tumors by inhibiting the generation of tumor blood vessels, and also can enhance the killing effect of the chemotherapeutic medicine on melanoma cells by inducing melanoma cell apoptosis. The TNFSF15 can enhance the melanoma treatment effect of cisplatin when used in combination with the chemotherapeuticmedicine cisplatin which is commonly used to treat melanoma.

The invention belongs to the technical field of traditional Chinese medicines, and particularly provides a preparation method and application of a Qingmei cold tablet. The preparation method comprises the following steps: by using 200g of southernwood, 267g of finger citron, 134g of elsholtzia, 200g of dicliptera, 134g of licorice, 134g of cat's-foot and 267g of holly root as active pharmaceutical ingredients, carrying out supercritical extraction and microwave extraction so that the glycyrrhizic acid content is greatly enhanced. The invention also provides application of the Qingmei cold tablet in preparing drugs for inhibiting mouse melanoma cell B16 from cell proliferation.

The invention discloses an attenuated salmonella mutant strain for slyA gene knockout, and application thereof. The attenuated salmonella mutant strain conducts knockout in attenuated salmonella VNP 20009 on a polynucleotide fragment of which the sequence is SEQ ID N0:2 (including an open reading frame of the slyA gene of which the sequence is SEQ ID N0:1 and six polynucleotide fragments on the upstream of the open reading frame), then a polynucleotide fragment of which the sequence is SEQ ID N0:3 is replaced for the slyA gene. The invention provides the application of the slyA gene deletion attenuated salmonella mutant strain in target mouse melanoma. A high targeting, brand new, safe, low-cost and convenient attenuated salmonella mutant strain of the target mouse melanoma and the application thereof are provided.